Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL – Get Rating) have earned a consensus rating of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $19.67.

A number of equities analysts have issued reports on VIGL shares. Morgan Stanley raised their target price on shares of Vigil Neuroscience from $11.00 to $12.00 and gave the stock an "equal weight" rating in a report on Monday, November 14th. Guggenheim lowered their price objective on shares of Vigil Neuroscience from $22.00 to $19.00 and set a "buy" rating on the stock in a research note on Friday, November 11th.

Institutional Trading of Vigil Neuroscience

Several institutional investors have recently made changes to their positions in VIGL. BVF Inc. IL acquired a new position in Vigil Neuroscience in the third quarter valued at about $16,504,000. Rock Springs Capital Management LP bought a new stake in shares of Vigil Neuroscience during the first quarter worth approximately $3,318,000. Vanguard Group Inc. bought a new stake in shares of Vigil Neuroscience during the first quarter worth approximately $2,708,000. BlackRock Inc. bought a new stake in Vigil Neuroscience in the first quarter valued at approximately $2,135,000. Finally, Laurion Capital Management LP bought a new stake in Vigil Neuroscience in the second quarter valued at approximately $336,000. 88.91% of the stock is currently owned by institutional investors and hedge funds.

Vigil Neuroscience Stock Up 0.4 %

Vigil Neuroscience (NASDAQ:VIGL – Get Rating) last posted its quarterly earnings data on Thursday, November 10th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.06. As a group, analysts expect that Vigil Neuroscience will post -2.25 earnings per share for the current fiscal year.

Vigil Neuroscience Company Profile

(Get Rating)

Vigil Neuroscience, Inc, a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease.

Read More

• Get a free copy of the StockNews.com research report on Vigil Neuroscience (VIGL)
• Insulet Has Potential To Gain More Than Analysts Are Forecasting
• Cathie Wood Is Buying These Stocks, Should You?
• Thor Industries Hammered Its Numbers. Is it a Buy?
• Tritium Is the Largest DC EV Charger Maker You've Never Heard Of
• United Airlines Soars Ahead of Earnings...Time to Deplane?

Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.